These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6968039)

  • 1. Serum 25-hydroxyvitamin D in patients with chronic renal failure on long-term treatment with high doses of vitamin D2.
    Fröhling PT; Kokot F; Vetter K; Kuska J; Kaschube I; Pietrek J
    Nephron; 1980; 26(3):116-20. PubMed ID: 6968039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of vitamin D metabolites in renal diseases.
    Ogura Y; Kawaguchi Y; Sakai S; Yamamoto M; Kimura Y; Oda Y; Imamura N; Tsukui I
    Contrib Nephrol; 1980; 22():18-27. PubMed ID: 6995016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D metabolites in serum from hypoparathyroid patients treated with vitamin D2 and 1 alpha-hydroxyvitamin D3.
    Aksnes L; Aarskog D
    J Clin Endocrinol Metab; 1980 Oct; 51(4):823-9. PubMed ID: 6968318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol.
    Gertner JM; Domenech M
    J Clin Pathol; 1977 Feb; 30(2):144-50. PubMed ID: 191473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D-deficiency in the elderly: treatment with ergocalciferol and hydroxylated analogues of vitamin D3.
    Shany S; Chaimovitz C; Yagev R; Bercovich M; Lowenthal MN
    Isr J Med Sci; 1988 Mar; 24(3):160-3. PubMed ID: 3259568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasma levels of 25-hydroxyvitamin D in patients with various liver diseases and the response of 25-hydroxyvitamin D to vitamin D treatment.
    Seino Y; Shimotsuji T; Kai H; Ikehara C; Yabuuchi H
    Acta Paediatr Scand; 1978 Jan; 67(1):39-42. PubMed ID: 305185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
    Hughes MR; Baylink DJ; Jones PG; Haussler MR
    J Clin Invest; 1976 Jul; 58(1):61-70. PubMed ID: 1084355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D.
    Zerwekh JE; Glass K; Jowsey J; Pak CY
    J Clin Endocrinol Metab; 1979 Aug; 49(2):171-5. PubMed ID: 313402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease.
    Doorenbos CR; de Cuba MM; Vogt L; Kema IP; van den Born J; Gans RO; Navis G; de Borst MH
    J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):56-61. PubMed ID: 21958677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.
    Compston JE; Horton LW; Thompson RP
    Gut; 1979 Feb; 20(2):133-6. PubMed ID: 311747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: a pilot trial.
    Del Valle E; Negri AL; Fradinger E; Canalis M; Bevione P; Curcelegui M; Bravo M; Puddu M; Marini A; Ryba J; Peri P; Rosa Diez G; Sintado L; Gottlieb E
    Hemodial Int; 2015 Jan; 19(1):60-5. PubMed ID: 25231816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D.
    Stamp TC; Haddad JG; Twigg CA
    Lancet; 1977 Jun; 1(8026):1341-3. PubMed ID: 69059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of vitamin D2 on hypocalcemia in patients under chronic hemodialysis.
    Kaneda H; Tobinai K; Matsumoto J; Maeta T; Murata T; Haruyama T; Imawari M
    Tohoku J Exp Med; 1980 Jul; 131(3):249-55. PubMed ID: 6968106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vitamin D deficiency and its correction in children with terminal stage of chronic kidney failure].
    Tsybysheva AK; Burkov IV; Blazhevich NV; Pereverzeva OG; Spirichev VB
    Vopr Med Khim; 1988; 34(4):112-7. PubMed ID: 3264096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency.
    Leventis P; Kiely PD
    Scand J Rheumatol; 2009; 38(2):149-53. PubMed ID: 18991184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D(3) is more potent than vitamin D(2) in humans.
    Heaney RP; Recker RR; Grote J; Horst RL; Armas LA
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E447-52. PubMed ID: 21177785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D metabolism in hypoparathyroidism.
    Lund B; Sørensen OH; Lund B; Bishop JE; Norman AW
    J Clin Endocrinol Metab; 1980 Sep; 51(3):606-10. PubMed ID: 6967875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis.
    Bell NH; Stern PH; Pantzer E; Sinha TK; DeLuca HF
    J Clin Invest; 1979 Jul; 64(1):218-25. PubMed ID: 312811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controlling renal osteopathy with keto acids].
    Schmicker R; Fröhling PT; Hohmann WD; Kokot F; Lindenau K; Vetter K
    Z Urol Nephrol; 1984 Nov; 77(11):661-70. PubMed ID: 6335331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.